Page last updated: 2024-12-08
sjg 136
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
1,1'-((propane-1,3-diyl)dioxy)bis(7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo(2,1-c)(1,4)benzodiazepin-5,11-dione): structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 393111 |
CHEMBL ID | 16498 |
SCHEMBL ID | 12020905 |
MeSH ID | M0475187 |
Synonyms (35)
Synonym |
---|
sjg 136 |
232931-57-6 |
NCI60_033825 |
up 2001 |
nsc694501 |
nsc-694501 |
5h-pyrrolo[2,4]benzodiazepin-5-one, 8,8'-[1,3-propanediylbis(oxy)]bis[1,2,3,11a-tetrahydro- 7-methoxy-2-methylene-, (11as, 11'as)- |
sg-2000 |
sjg-136 |
CHEMBL16498 |
up-2001 |
sp-2001 |
bn-2629 |
(6as)-3-[3-[[(6as)-2-methoxy-8-methylidene-11-oxo-7,9-dihydro-6ah-pyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]propoxy]-2-methoxy-8-methylidene-7,9-dihydro-6ah-pyrrolo[2,1-c][1,4]benzodiazepin-11-one |
kt0zq64x1a , |
unii-kt0zq64x1a |
sjg136 |
1,1'-((propane-1,3-diyl)dioxy)bis(7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5h-pyrrolo(2,1-c)(1,4)benzodiazepin-5,11-dione) |
nsc 694501 |
CS-4593 |
SCHEMBL12020905 |
HY-14573 |
sjg 136 [who-dd] |
(6as)-3-(3-(((6as)-2-methoxy-8-methylene-11-oxo-7,9-dihydro-6ah-pyrrolo(2,1-c)(1,4)benzodiazepin-3-yl)oxy)propoxy)-2-methoxy-8-methylene-7,9-dihydro-6ah-pyrrolo(2,1-c)(1,4)benzodiazepin-11-one |
5h-pyrrolo(2,1-c)(1,4)benzodiazepin-5-one, 8,8'-(1,3-propanediylbis(oxy))bis(1,2,3,11a-tetrahydro-7-methoxy-2-methylene-, (11as,11'as)- |
DTXSID20177864 |
AKOS027326601 |
DB11965 |
(11as,11a's)-8,8'-(propane-1,3-diylbis(oxy))bis(7-methoxy-2-methylene-1,2,3,11a-tetrahydro-5h-benzo[e]pyrrolo[1,2-a][1,4]diazepin-5-one) |
5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one, 8,8'-[1,3-propanediylbis(oxy)]bis[1,2,3,11a-tetrahydro-7-methoxy-2-methylene-, (11as,11'as)- |
Q27282424 |
C74198 |
A858346 |
(11as,11a's)-8,8'-(propane-1,3-diylbis(oxy))bis(7-methoxy-2-methylene-1,2,3,11a-tetrahydro-5h-benzo[e]pyrrolo[1,2-a][1,4]diazepin-5-one);1,1'-(propane-1,3-diylbis(oxy))bis(7-methoxy-2-methylene-1,2,3,11a-tetrahydro-5h-benzo[e]pyrrolo[1,2-a][1,4]diazepine- |
BS-42683 |
Research Excerpts
Pharmacokinetics
Dosage Studied
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (30)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID224602 | Compound dose required to induce 50 percent cross linking in naked plasmid pBR322 DNA following incubation with agent for 2 hours at 37 degree C | 2004 | Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5 | Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers. |
AID94620 | Dose required to induce 50 percent decrease in tail moment of the DNA of K562 cells following a 1 hour treatment | 2004 | Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5 | Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers. |
AID321351 | Cytotoxicity against human NCI60 cells | 2008 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6 | An asymmetric C8/C8'-tripyrrole-linked sequence-selective pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimer DNA interstrand cross-linking agent spanning 11 DNA base pairs. |
AID471718 | Cytotoxicity against human K562 cells by alamar blue assay | 2009 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22 | Synthesis of a novel C2/C2'-aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine dimer prodrug with improved water solubility and reduced DNA reaction rate. |
AID392957 | Binding affinity to calf thymus DNA assessed as change in melting temperature at a compound to DNA molar ratio of 1:5 at pH 7 by thermal denaturation assay | 2009 | Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4 | Remarkable enhancement in the DNA-binding ability of C2-fluoro substituted pyrrolo[2,1-c][1,4]benzodiazepines and their anticancer potential. |
AID54323 | Thermal stabilization of duplex form of calf thymus DNA after incubation for 0 hours | 2004 | Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5 | Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers. |
AID230366 | Resistance factor (IC50 resistant/ parent) | 2001 | Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21 | Synthesis of the first example of a C2-C3/C2'-C3'-endo unsaturated pyrrolo[2,1-c][1,4]benzodiazepine dimer. |
AID10018 | Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay | 2001 | Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5 | Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. |
AID94817 | Inhibitory concentration against human K562 leukemia cells following incubation for 1 hour | 2004 | Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5 | Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers. |
AID47514 | Inhibition of cell growth in human ovarian carcinoma cell line (CH1-cis-R,cisplatin resistant) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay | 2001 | Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5 | Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. |
AID202838 | Inhibition of cell growth in human ovarian carcinoma cell line(SKOV-3) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay | 2001 | Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5 | Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. |
AID232613 | Ratio of IC50 against human ovarian carcinoma cell line (CH1)cisR (cisplatin resistant) to the IC50 of parent | 2001 | Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5 | Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. |
AID249980 | Increase in melting point temperature after 18 hr of incubation [1:5] as measurement of DNA binding affinity using calf thymus DNA | 2004 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22 | Synthesis of fluorinated analogues of SJG-136 and their DNA-binding potential. |
AID321352 | Cytotoxicity against human K562 cells | 2008 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6 | An asymmetric C8/C8'-tripyrrole-linked sequence-selective pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimer DNA interstrand cross-linking agent spanning 11 DNA base pairs. |
AID276048 | Induction of linear pBR322 DNA interstrand crosslinking | 2006 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21 | DNA interstrand crosslinking agents: synthesis, DNA interactions, and cytotoxicity of dimeric achiral seco-amino-CBI and conjugates of achiral seco-amino-CBI with pyrrolobenzodiazepine (PBD). |
AID270008 | Cytotoxicity against human NCI60 cell line by MTT assay | 2006 | Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18 | Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates. |
AID54325 | Thermal stabilization of duplex form of calf thymus DNA after incubation for 4 hours | 2004 | Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5 | Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers. |
AID321353 | Induction of cross linking in DS pUC18 plasmid | 2008 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6 | An asymmetric C8/C8'-tripyrrole-linked sequence-selective pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimer DNA interstrand cross-linking agent spanning 11 DNA base pairs. |
AID10017 | Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay | 2001 | Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21 | Synthesis of the first example of a C2-C3/C2'-C3'-endo unsaturated pyrrolo[2,1-c][1,4]benzodiazepine dimer. |
AID270012 | Cytotoxicity against human K562 cell line after 96 hrs by MTT assay | 2006 | Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18 | Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates. |
AID41578 | Compound was tested for inhibition of restriction endonuclease BamH1 enzyme at a concentration of 17.5 uM;Inhibited | 2004 | Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5 | Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers. |
AID225423 | The concentration of compound required for 50% cross linking of plasmid pBR322 DNA was investigated using an assay involving linear double stranded DNA | 2001 | Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5 | Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. |
AID249982 | Increase in melting point temperature after 0h of incubation [1:5 ratio] as measurement of DNA binding affinity using calf thymus DNA | 2004 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22 | Synthesis of fluorinated analogues of SJG-136 and their DNA-binding potential. |
AID9821 | Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay | 2001 | Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5 | Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. |
AID47512 | Inhibition of cell growth in human ovarian carcinoma cell line (CH1) was determined using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay. | 2001 | Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5 | Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. |
AID94467 | Inhibition of cell growth by 50% in human leukemia cell line (K562) was determined using microculture tetrazolium (MTT) assay. | 2001 | Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5 | Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. |
AID232609 | Ratio of IC50 against A2780cisR (cisplatin resistant) to the IC50 of parent | 2001 | Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5 | Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. |
AID10016 | Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay | 2001 | Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21 | Synthesis of the first example of a C2-C3/C2'-C3'-endo unsaturated pyrrolo[2,1-c][1,4]benzodiazepine dimer. |
AID54324 | Thermal stabilization of duplex form of calf thymus DNA after incubation for 18 hours | 2004 | Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5 | Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers. |
AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (37)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 27 (72.97) | 29.6817 |
2010's | 9 (24.32) | 24.3611 |
2020's | 1 (2.70) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 21.19
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.19) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 3 (8.11%) | 5.53% |
Reviews | 2 (5.41%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 32 (86.49%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |